Clinical Trials Logo

Clinical Trial Summary

In this clinical study silymarin will be administered in different dosages and compared to placebo in order to address if the liver protecting features of silymarin, measured by changes of liver enzyme concentration, can be improved in patients with drug-induced elevated liver enzymes or drug-induced hepatocellular liver injury with higher systemic bioavailabilities due to administration of higher oral dosages or administration of higher administration frequency over a 35-day treatment period.


Clinical Trial Description

In clinical routine care, drug-induced elevation of liver enzymes occurs often in parallel to new treatment initiation, possibly leading to interruption of treatment strategies if liver enzyme elevation does not normalize within 2 to 4 weeks. Liver injury from medications usually occurs within 6 months of drug initiation and typically within the first 1-4 weeks1. In general, drug-induced liver injury (DILI) is related to the class of drug, the quantity of drug consumed, the patient's age and sex, and such concurrent factors as diabetes mellitus, excessive alcohol intake, e.g. high caloric diet, which can lead to NAFLD/steatosis, or the use of other medications. Drugs administered in higher doses are more likely to cause liver injury, especially drugs that require extensive hepatic metabolism1. Different forms of drug-induced elevation of liver enzymes can be differentiated according to localisation of the injury: hepatocellular or cholestatic liver injury or a mixture of both.Besides methotrexate and isozid, other medications have been reported to induce hepatocellular liver injury: acarbose, allopurinol, amiodarone, baclofen, bupropion, fluoxetine, ketoconazole, lisinopril, losartan, non-steroidal anti-inflammatory drugs (NSAIDs), omeprazole, paracetamol, paroxetine, pyrazinamide, rifampicin, risperidone, sertraline, statins, tetracyclines, trazodone, and valproic acid. Silymarin containing oral preparations are widely used for their liver protecting characteristics. The milk thistle ingredient silibinin is registered for continuous intravenous administration in the case of acute liver intoxications such as consumption of amanita mushrooms. Although its mode of action is still not clear, the clinical therapeutic benefits in patients with liver diseases are documented. Pharmacokinetics of silymarin after oral administration are well understood. Due to its poor solubility in aqueous media, absorption from the intestinal tract is generally limited. Silymarin's systemic bioavailability of marketed products is therefore rather low, also because of predominant first pass biliary elimination. Exact PK/PD relations of the compound have not been assessed so far. Hence, in this clinical study silymarin will be administered in different dosages and compared to placebo in order to address the following question: Can liver protecting features of silymarin, measured by changes of liver enzyme concentration, be improved in patients with drug-induced elevated liver enzymes or drug-induced hepatocellular liver injury with higher systemic bioavailabilities due to administration of higher oral dosages or administration of higher administration frequency over a 35-day treatment period? ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05144217
Study type Interventional
Source Fraunhofer Institute for Molecular Biology and Applied Ecology
Contact
Status Active, not recruiting
Phase Phase 2/Phase 3
Start date June 23, 2021
Completion date December 31, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT05517668 - Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose Phase 2
Recruiting NCT05060289 - A Prognostic Model for Drug-induced Liver Injury in China
Completed NCT03092817 - Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial) Phase 3
Completed NCT03211208 - Assessing Antibiotic Induced Liver Injury for Stratification of Tuberculosis Patients
Completed NCT02182167 - A Trial Of Intravenous N-Acetylcysteine In The Management Of Antituberculous Drug-Induced Hepatitis Phase 2/Phase 3
Not yet recruiting NCT02061826 - Establishment of Drug-induced Liver Injury Databases and Application of Circulating microRNA(miRNA) N/A
Completed NCT03665402 - A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status N/A
Not yet recruiting NCT03091556 - Surveillance for Early Liver Injuries Caused by Xianlin Gubao Pill. N/A
Not yet recruiting NCT03091218 - Surveillance for Early Liver Injuries Caused by Runzao Zhiyang Capsule. N/A
Not yet recruiting NCT03091608 - Surveillance for Early Liver Injuries Caused by Xianlin Gubao Granule N/A
Not yet recruiting NCT03060252 - Surveillance for Early Liver Injuries Caused by Zhuanggu Guanjie Pill N/A
Not yet recruiting NCT03091244 - Surveillance for Early Liver Injuries Caused by Xianlin Gubao Capsule. N/A
Completed NCT02407964 - A Retrospective Study on Drug Induced Liver Injury in China N/A
Completed NCT01705041 - Preliminary Evaluation of a Point-Of-Care Liver Function Test N/A
Recruiting NCT02086708 - Ultrasound Method to Measure Fibrosis of the Liver in Children N/A
Recruiting NCT05465642 - Alterations of Gut Microbiota and Serum Biochemical Markers in DILI Patients
Completed NCT01434173 - Risk of Acute Liver Injury in Users of Antimicrobials N/A
Completed NCT05532345 - Discrimination of DILI and AIH by Artificial Intelligence
Completed NCT03602703 - Immune Responses in Hepatocellular Carcinoma Patients After Treatment With Direct Acting Antiviral Drugs
Active, not recruiting NCT03100786 - Leukotriene A4 Hydrolase Stratified Trial of Adjunctive Corticosteroids for HIV-uninfected Adults With Tuberculous Meningitis Phase 3